Media.Player

Use of Neurotrophic Factors in Treating Memory Loss and Neurodegenerative Disease

技術應用

The method is useful in the therapy of defective, diseased, and damaged neurons in the brain for normal aging or in treating neurodegeneration of the type associated with Alzheimer's disease and Parkinson's.

詳細技術說明

UC San Diego researchers have shown that nervous system growth factors BDNF and NT-4/5 have efficacy in reversing age-related memory impairment and enhance neuronal structure when delivered to the entorhinal cortex. The invention includes the specific administration protocols needed to effectively deliver this factor with minimal side effects.

*Abstract

Recently, clinical trials that genetically express the nerve growth factor gene in the brain have shown efficacy in treating patients with Alzheimer's disease.

*IP Issue Date

Aug 17, 2010

*Principal Investigation

Name: Andrea Chiba

Department:

Name: James Conner

Department:

Name: David Merrill

Department:

Name: Mark Tuszynski

Department:

附加資料

Patent Number: US7776320B2
Application Number: US2006431436A
Inventor: Tuszynski, Mark H.
Priority Date: 31 Dec 2001
Priority Number: US7776320B2
Application Date: 10 May 2006
Publication Date: 17 Aug 2010
IPC Current: A01N006300 | A61K003822 | A01N004304 | A01N006500 | A61K003170 | A61K003818 | A61K004800 | A61P002500 | A61P002528
US Class: 4240931 | 4240932 | 42409321 | 514044R | 514044
Assignee Applicant: The Regents of the University of California
Title: Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
Usefulness: Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
Summary: The method is useful for stimulating or supporting cortical neurons in a subject's brain, where the subject is human or aged. The human is suffering from Alzheimer's disease, and the disease is ameliorated by stimulation of growth or activity in neurons of entorhinal cortex. The disease is ameliorated by reversal of deficits in cognitive function associated with Alzheimer's disease (claimed).

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

7776320

其他

State Of Development

The genes have been tested successfully in animal models, and the administration protocols have been tested successfully in human clinical trials.

Related Materials

• Tuszynski MH, Mafong E, Meyer S. Central Infusions of Brain-Derived Neurotrophic Factor and Neurotrophin-4/5, but not Nerve Growth Factor and Neurotrophin-3, Prevent Loss of the Cholinergic Phenotype in Injured Adult Motor Neurons. Neuroscience. 1996 Apr;71(3):761-71.
• Lu P, Blesch A, Tuszynski MH. Neurotrophism Without Neurotropism: BDNF Promotes Survival but not Growth of Lesioned Corticospinal Neurons. J Comp Neurol. 2001 Aug 6;436(4):456-70.
• Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Tessler A, Murray M. Delayed Grafting of BDNF and NT-3 Producing Fibroblasts into the Injured Spinal Cord Stimulates Sprouting, Partially Rescues Axotomized Red Nucleus Neurons from Loss and Atrophy, and Provides Limited Regeneration. Exp Neurol. 2003 Nov;184(1):97-113.

Tech ID/UC Case

19509/2001-109-0

Related Cases

2001-109-0

國家/地區

美國